Pfizer and BioNTech’s COVID-19/Flu Vaccine Misses Key Endpoint in Phase 3 Study

Introduction

Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers’ combined COVID-19 and flu vaccine in adults. The experimental vaccine missed one of two key endpoints in a Phase 3 study, raising concerns about its effectiveness against influenza B.

Phase 3 Trial Results

The Phase 3 trial of the Pfizer-BioNTech COVID-19 drug and Pfizer’s flu medicine showed positive responses against COVID-19 and influenza A viruses. However, it fell short in providing protection against influenza B. While the vaccine demonstrated efficacy against two out of three targeted viruses, the failure to meet the endpoint for influenza B is a setback for the companies.

Evaluating Adjustments

Pfizer and BioNTech have stated that they are evaluating adjustments to the vaccine based on the trial results. They plan to discuss the findings with health officials and explore ways to enhance the vaccine’s effectiveness against influenza B. The companies remain committed to developing combination vaccines that offer broader protection against multiple respiratory diseases.

Insights for Further Development

Dr. Ugur Sahin, CEO of BioNTech, emphasized the value of the insights gained from the trial. He stated that the findings would play a crucial role in guiding the further development of combination vaccines. Pfizer also provided an update on a Phase 2 study of its experimental second-generation trivalent influenza mRNA vaccine. The study showed encouraging data, demonstrating robust immunogenicity against all strains compared to a standard of care influenza vaccine.

Market Reaction

Following the announcement, Pfizer shares and BioNTech ADRs experienced a decline in value. Pfizer shares slipped 1.9%, while BioNTech ADRs dropped 2.9% as of 1:30 p.m. ET on Friday. BioNTech ADRs have seen a decline of approximately 20% in 2024. Investors are closely monitoring the companies’ next steps and the potential impact on their market performance.

Conclusion

The disappointing results from the Phase 3 study of Pfizer and BioNTech’s combined COVID-19 and flu vaccine highlight the challenges in developing effective vaccines against multiple respiratory diseases. While the vaccine showed efficacy against COVID-19 and influenza A, it fell short in providing protection against influenza B. Pfizer and BioNTech are now evaluating adjustments to enhance the vaccine’s effectiveness. The insights gained from this trial will guide the further development of combination vaccines. Investors will be watching closely for updates on the companies’ progress and the potential impact on their market performance.

Read the original article on Investopedia.